Siemens Fonds Invest GmbH Makes New Investment in DaVita Inc. (NYSE:DVA)

Siemens Fonds Invest GmbH purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,035 shares of the company's stock, valued at approximately $603,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DVA. Assenagon Asset Management S.A. increased its holdings in DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock valued at $11,159,000 after buying an additional 49,885 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in DaVita by 19.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 30,769 shares of the company's stock valued at $4,601,000 after purchasing an additional 4,942 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in DaVita by 10.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 40,500 shares of the company's stock worth $6,057,000 after purchasing an additional 3,680 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in DaVita by 1.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 25,020 shares of the company's stock worth $3,742,000 after purchasing an additional 429 shares in the last quarter. Finally, Secure Asset Management LLC acquired a new stake in DaVita in the fourth quarter valued at $208,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DVA. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $166.33.

DaVita Trading Up 1.1%

Shares of DVA stock opened at $145.23 on Friday. DaVita Inc. has a twelve month low of $131.44 and a twelve month high of $179.60. The company has a market capitalization of $11.16 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.07 and a beta of 1.14. The firm has a 50-day moving average price of $145.68 and a 200 day moving average price of $153.48. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.26 earnings per share. Research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.